Teva up 4% premarket on Q2 revenue beat

Teva Pharmaceutical Industries (NYSE:TEVA) Q2 results ($M): Revenues: 4,337 (-7.7%); Generics: 2,279 (-4.7%).

Net income: (689) (-291.5%); non-GAAP net income: 653 (-17.8%); EPS: (0.63) (-162.5%); non-GAAP EPS: 0.60 (-23.1%).

Key product sales: Copaxone: 274 (-40.9%); Treanda/Bendeka: 115 (-28.1%); ProAir: 65 (-43.5%); Qvar: 60 (+100.0%); Ajovy: 23.

Cash flow ops: (227) (-240.1%).

Shares up 4% premarket on light volume.

Previously: Teva Pharmaceutical EPS beats by $0.02, beats on revenue(Aug. 7)

https://seekingalpha.com/news/3488305-teva-4-percent-premarket-q2-revenue-beat